CareDx to Host Investor Day on October 15, 2024
- BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers — today announced the Company will be hosting an Investor Day on October 15, 2024, in New York City, New York, starting at 8:00 a.m. Eastern Time / 5:00 a.m. Pacific Time. The event will feature presentations.
- 10/08/2024
|
CareDx Announces Closure of DOJ Investigation with No Finding of Wrongdoing
- BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ – a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that the Department of Justice (DOJ) has concluded its investigation into CareDx with no finding of wrongdoing and declined to take any further action. In a Court document unsealed on October.
- 10/08/2024
|
CareDx Inc (CDNA) Trading 6.16% Higher on Oct 2
- Shares of CareDx Inc (CDNA, Financial) surged 6.16% in mid-day trading on Oct 2. The stock reached an intraday high of $32.97, before settling at $32.83, up from its previous close of $30.93.
- 10/02/2024
|
CAREDX INVESTIGATION CONTINUED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of CareDx, Inc. - CDNA
- NEW ORLEANS, LA / ACCESSWIRE / September 30, 2024 / Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq.
- 09/30/2024
|
CareDx Resolves Key Issues: Poised For Growth In Transplant Diagnostics
- CDNA has resolved corporate instability and insurance issues, showing potential for sustainable growth with innovative transplant testing services like AlloSure, AlloMap, and HeartCare. CDNA's products are supported by scientific literature and recent Medicare coverage expansions, enhancing their market potential and revenue growth prospects. The appointment of CEO John W. Hanna provides stable leadership and strategic direction for long-term objectives.
- 09/29/2024
|
SHAREHOLDER ALERT: Morris Kandinov Investigating CareDx, Inc., Puerto Rico Residents Tax-Free Fund, Inc., Puerto Rico Residents Tax-Free Fund VI, Inc., and Tax Free Fund for Puerto Rico Residents, Inc.; Shareholders are Encouraged to Contact the Firm
- Morris Kandinov Investigating CareDx, Inc., Puerto Rico Residents Tax-Free Fund, Inc., Puerto Rico Residents Tax-Free Fund VI, Inc., and Tax Free Fund.
- 09/24/2024
|
CareDx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA)- The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers — today announced that, on September 12, 2024, CareDx granted an option to purchase 100,651 shares of CareDx's common stock (the “Kennedy Inducement Option”) and 70,101 restricted stock units (the “Kennedy Indu.
- 09/13/2024
|
CareDx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers — today announced that, as an inducement material to entering into employment with CareDx, on September 12, 2024, 14 new employees were awarded restricted stock units (RSUs) for an aggregate of 44,000 shares o.
- 09/13/2024
|
CareDx, Inc. (CDNA) Hit a 52 Week High, Can the Run Continue?
- CareDx (CDNA) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
- 08/09/2024
|
CareDx (CDNA) Upgraded to Strong Buy: What Does It Mean for the Stock?
- CareDx (CDNA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
- 08/07/2024
|
Compared to Estimates, CareDx (CDNA) Q2 Earnings: A Look at Key Metrics
- The headline numbers for CareDx (CDNA) give insight into how the company performed in the quarter ended June 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
- 07/31/2024
|
CareDx, Inc. (CDNA) Q2 2024 Earnings Call Transcript
- CareDx, Inc. (NASDAQ:CDNA ) Q2 2024 Earnings Conference Call July 31, 2024 4:30 PM ET Company Participants Greg Chodaczek - Managing Director John Hanna - President and CEO Abhishek Jain - Chief Financial Officer Robert Woodward - Chief Scientific Officer Alex Johnson - President, Patient and Testing Services Conference Call Participants Bill Bonello - Craig-Hallum Kayla Hostetler - Jefferies Prashant Kota - Goldman Sachs Andrew Cooper - Raymond James Nathan Kariko - Stephens Vivian Bais - BTIG Yi Chen - H.C. Wainwright Thomas DeBourcy - Nephron Research Operator Good day, everyone.
- 07/31/2024
|
CareDx (CDNA) Q2 Earnings and Revenues Beat Estimates
- CareDx (CDNA) came out with quarterly earnings of $0.25 per share, beating the Zacks Consensus Estimate of a loss of $0.13 per share. This compares to loss of $0.18 per share a year ago.
- 07/31/2024
|
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of CareDx, Inc. (NASDAQ: CDNA)
- NEW YORK , July 16, 2024 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating CareDx, Inc. (NASDAQ: CDNA) on behalf of the company's shareholders. The investigation seeks to determine whether CareDx's directors breached their fiduciary duties in connection with recent corporate actions.
- 07/16/2024
|
Landmark Independent Publication in Nature Medicine Validates CareDx AlloView AI-Enabled Risk Prediction Model and Demonstrates AlloSure Kidney Detects Subclinical Rejection in Stable Patients
- BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced in conjunction with the 2024 American Transplant Congress, the publication in Nature Medicine1 of findings from the largest, real-world study of its kind, assessing the role of AlloSure® donor-derived cell-free DNA (dd-cfDNA) and.
- 06/03/2024
|
AI Integration and Real-World Utility of CareDx Portfolio Highlighted in New Data at the 2024 American Transplant Congress
- BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ – a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced new data to be presented at the 2024 American Transplant Congress (ATC) being held June 1-5 in Philadelphia. CareDx solutions are featured in 36 oral presentations and posters, and a symposiu.
- 05/30/2024
|
CareDx Reiterates Position that it Does Not Infringe the ‘544 Patent, Injunction Motion is Irrelevant
- BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today responded to Natera, Inc.'s filing of a motion for an injunction related to patent 11,111,544 (the ‘544 patent). The motion seeks to stop CareDx from using a prior AlloSure® process that Natera alleged infringed the ‘544 patent. That proces.
- 05/29/2024
|
CareDx to Participate in Upcoming Investor Conferences
- BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA), The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that the Company will participate in two upcoming investor conferences. CareDx's management is scheduled to present at the: Jefferies Global Healthcare Conference on Thursday, June 6, 2023, at.
- 05/29/2024
|
Landmark Study Shows CareDx's HeartCare Outperforms dd-cfDNA Alone in Identifying Rejection and Patients Experienced Excellent Outcomes with Fewer Biopsies
- BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ – a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced findings from the SHORE (Surveillance HeartCare Outcomes Registry) study, one of the largest heart transplant studies of its kind, published in The Journal of Heart and Lung Transplantation.
- 05/16/2024
|
CareDx, Inc. (CDNA) Q1 2024 Earnings Call Transcript
- CareDx, Inc. (NASDAQ:CDNA ) Q1 2024 Earnings Conference Call May 9, 2024 4:30 PM ET Company Participants Greg Chodaczek - Managing Director of Investor Relations John Hanna - President & Chief Executive Officer Abhishek Jain - Chief Financial Officer Alex Johnson - President-Patient & Testing Services Conference Call Participants Bill Bonello - Craig-Hallum Capital Group Prashant Kota - Goldman Sachs Mason Carrico - Stephens Operator Good day, everyone, and welcome to today's CareDx, Inc. First Quarter 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode.
- 05/09/2024
|
CareDx (CDNA) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
- Although the revenue and EPS for CareDx (CDNA) give a sense of how its business performed in the quarter ended March 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
- 05/09/2024
|
CareDx Reports First Quarter 2024 Results
- BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – today reported financial results for the first quarter ended March 31, 2024. First Quarter 2024 Highlights Reported first quarter revenue of $72.0 million. Revenue for Testing Services of $53.8 million, an increase of 15% as compared to the fourth quarter 2023. Grew testing services patients results for the third consecutive quarter to approximately 42,000, an increase of 6% as compared to the fourth quarter 2023. Over 30 oral pre.
- 05/09/2024
|
CareDx (CDNA) Q1 Earnings Preview: What You Should Know Beyond the Headline Estimates
- Beyond analysts' top -and-bottom-line estimates for CareDx (CDNA), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended March 2024.
- 05/07/2024
|
CareDx Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
- BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers — today announced that, as an inducement material to entering into employment with CareDx, on April 19, 2024, 17 new employees were awarded restricted stock units (RSUs) for an aggregate of 54,350 shares of co.
- 05/03/2024
|
CareDx to Report First Quarter 2024 Financial Results
- BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced it will report financial results for the first quarter 2024 after market close on Thursday, May 9, 2024. Company management will host a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. In.
- 04/29/2024
|
CareDx Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
- BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers — today announced that, on April 15, 2024, CareDx granted an option to purchase 700,706 shares of CareDx's common stock (the “Inducement Option”) and 487,804 restricted stock units (the “Inducement RSUs” ) to.
- 04/19/2024
|
CareDx (CDNA) Moves 5.5% Higher: Will This Strength Last?
- CareDx (CDNA) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
- 04/18/2024
|
CareDx Appoints John W. Hanna as its New President and Chief Executive Officer
- BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ – a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients – has appointed John W. Hanna as its new President and Chief Executive Officer, and member of the Company's Board of Directors, effective April 15, 2024. “John is an outstanding leader with a proven track record of building.
- 04/16/2024
|
CareDx and Collaborators Present Latest Cardiothoracic Advancements at the 2024 International Society for Heart and Lung Transplantation Meeting
- BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA)- The Transplant Company™ – a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that CareDx and study collaborators will be presenting the latest data featuring CareDx's cardiothoracic portfolio at the International Society for Heart and Lung Transplantation (ISHLT) 44th.
- 04/09/2024
|
How CareDx (CDNA) Stock Stands Out in a Strong Industry
- CareDx (CDNA) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
- 04/01/2024
|
CareDx Appoints Bryan Riggsbee to Its Board of Directors
- BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers — today announced that Bryan Riggsbee joins CareDx's Board of Directors, effective March 11, 2024. “We're pleased to welcome Bryan to our Board,” said Michael Goldberg, CareDx Board Chairperson. “His financial.
- 03/11/2024
|
CareDx, Inc. (CDNA) Q4 2023 Earnings Call Transcript
- CareDx, Inc. (CDNA) Q4 2023 Earnings Call Transcript
- 02/28/2024
|
CareDx (CDNA) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
- Although the revenue and EPS for CareDx (CDNA) give a sense of how its business performed in the quarter ended December 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
- 02/28/2024
|
CareDx Announces Fourth Quarter and Full Year 2023 Financial Results
- BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) today reported financial results for the fourth quarter and full year ended December 31, 2023. Fourth Quarter and Full Year 2023 Highlights Reported full year revenue of $280.3 million, exceeding the high end of updated guidance for 2023. Reported full year Testing Services revenue of $209.7 million and delivered approximately 165,700 patient results in 2023. Grew Testing Services patient results for the second quarter in a row to a.
- 02/28/2024
|
Unlocking Q4 Potential of CareDx (CDNA): Exploring Wall Street Estimates for Key Metrics
- Beyond analysts' top -and-bottom-line estimates for CareDx (CDNA), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended December 2023.
- 02/26/2024
|
CareDx to Report Fourth Quarter and Full Year 2023 Financial Results
- BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced it will report financial results for the fourth quarter and full year 2023 after market close on Wednesday, February 28, 2024. Company management will host a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30.
- 02/21/2024
|
CareDx Showcases Digital Solutions and Pipeline in Cellular Transplant and Therapy Monitoring at the 2024 Tandem Meetings
- BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) —The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers — today announced that it will be showcasing the breadth of its specialized digital solutions and the latest advancements in its cellular therapy and transplant monitoring pipeline at the 2024 Tandem Meetings,.
- 02/21/2024
|
CareDx Issues Statement in Patent Infringement Case
- BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced the jury verdict in the patent litigation brought by Natera, Inc. (Nasdaq: NTRA). CareDx was found to have not infringed on Natera patent 10,655,180 (the ‘180 patent) and found to have infringed on Natera patent 11,111,544 (the ‘5.
- 01/26/2024
|
CareDx Adds to AlloSure Kidney and HeartCare Utility and Clinical Data at 2024 American Society of Transplant Surgeons Winter Symposium
- BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced a leading presence and the fifth consecutive year as the Distinguished Founder's Circle Sponsor for the Annual American Society of Transplant Surgeons (ASTS) Winter Symposium being held January 11 - 14, 2024 in Miami, Florida. Car.
- 01/11/2024
|
How Much Upside is Left in CareDx (CDNA)? Wall Street Analysts Think 26.72%
- The average of price targets set by Wall Street analysts indicates a potential upside of 26.7% in CareDx (CDNA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
- 12/08/2023
|
Can CareDx (CDNA) Climb 29.79% to Reach the Level Wall Street Analysts Expect?
- The mean of analysts' price targets for CareDx (CDNA) points to a 29.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
- 11/22/2023
|
CareDx, Inc (CDNA) Q3 2023 Earnings Call Transcript
- CareDx, Inc (NASDAQ:CDNA ) Q3 2023 Results Conference Call November 8, 2023 4:30 PM ET Company Participants Greg Chodaczek - Gilmartin Group, Managing Director Alex Johnson - President of Patient and Testing Services Abhishek Jain - Chief Financial Officer Robert Woodward - Chief Scientific Officer Michael Goldberg - Chairperson of the Board Conference Call Participants Andrew Cooper - Raymond James Alex Nowak - Craig-Hallum Capital Group Jacob Krahenbuhl - Stephens Dipesh Patel - H.C. Weinright Operator Good day, everyone, and welcome to today's CareDx Inc. Third Quarter 2023 Earnings Conference Call.
- 11/08/2023
|
CareDx (CDNA) Surges 16.6%: Is This an Indication of Further Gains?
- CareDx (CDNA) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
- 11/06/2023
|
Compared to Estimates, CareDx (CDNA) Q2 Earnings: A Look at Key Metrics
- Although the revenue and EPS for CareDx (CDNA) give a sense of how its business performed in the quarter ended June 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
- 08/09/2023
|
CareDx (CDNA) Reports Q2 Loss, Tops Revenue Estimates
- CareDx (CDNA) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.42. This compares to loss of $0.13 per share a year ago.
- 08/08/2023
|
CareDx (CDNA) Soars 20.6%: Is Further Upside Left in the Stock?
- CareDx (CDNA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
- 07/10/2023
|
Why Shares of CareDx Are Jumping Friday
- CareDx specializes in diagnostic testing for transplant patients. The company's revenue declined 3% year over year in the first quarter.
- 07/07/2023
|
CareDx to Participate in Upcoming Investor Conferences
- BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that the Company will participate in two upcoming investor conferences. CareDx's management is scheduled to present at the Jefferies Global Healthcare Conference on Thursday, June 8, 2023, at 8:00 AM PT / 11:00 AM ET.
- 06/01/2023
|
CareDx to Report First Quarter 2023 Financial Results
- BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced it will report financial results for the first quarter 2023 after market close on Wednesday, May 10, 2023. Company management will host a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
- 05/08/2023
|
CareDx, Inc. (CDNA) Q4 2022 Results Earnings Call Transcript
- CareDx, Inc. (NASDAQ:CDNA ) Q4 2022 Earnings Conference Call February 27, 2023 4:30 PM ET Company Participants Greg Chodaczek - IR Reginald Seeto - CEO Abhishek Jain - Interim CFO Conference Call Participants Andrew Cooper - Raymond James Matthew Sykes - Goldman Sachs Mason Carrico - Stephens Alex Nowak - Craig-Hallum Capital Group Mark Massaro - BTIG Yi Chen - H.C. Wainright Operator Good day, ladies and gentlemen, and welcome to the CareDx, Incorporated Fourth Quarter 2022 Earnings Conference Call.
- 02/27/2023
|
CareDx (CDNA) Reports Q4 Loss, Tops Revenue Estimates
- CareDx (CDNA) delivered earnings and revenue surprises of -16.67% and 0.38%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
- 02/27/2023
|
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
- The growth-focused money manager is making moves.
- 01/27/2023
|
CareDx: What To Make Of The New Share Repurchase Program (Rating Upgrade)
- CDNA's share repurchase program will reduce outstanding shares by 8% based on current prices. This and management's short-term profitability ambitions warrant a rating upgrade. The company has a strong balance sheet, with enough dry powder to leverage itself into profitability as it gradually winds down its growth initiatives.
- 12/12/2022
|
Here's Why CareDx (CDNA) Could be Great Choice for a Bottom Fisher
- CareDx (CDNA) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
- 11/17/2022
|
CareDx (CDNA) Loses 22.5% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
- CareDx (CDNA) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
- 11/11/2022
|
CareDx, Inc. (CDNA) CEO Reg Seeto on Q3 2022 Results - Earnings Call Transcript
- CareDx, Inc (NASDAQ:CDNA ) Q3 2022 Earnings Conference Call November 3, 2022 4:30 PM ET Company Participants Ian Cooney - VP, IR Reg Seeto - CEO Abhishek Jain - Interim CFO Conference Call Participants Brandon Couillard - Jefferies Operator Good day, ladies and gentlemen, and welcome to the CareDx, Incorporated Third Quarter 2022 Earnings Conference Call. Today's conference is being recorded.
- 11/03/2022
|
CareDx: Shaking Off First-Mover Disadvantage
- The introduction of new products and the further extension of reimbursement routes are projected to fuel CDNA growth. CDNA is renewing its emphasis on profitability after a widening loss caused a 14% share decline in August after the Q2 earnings release.
- 10/18/2022
|
5 Top Stocks Cathie Wood Is Buying This Week
- Last week, Cathie Wood made headlines after it was announced that she would relinquish her position as portfolio manager over two of her exchange-traded funds (ETFs), the 3D Printing ETF (BATS: PRNT ) and the ARK Israel Innovative Technology ETF (BATS: IZRL ). This led to speculation that the 66-year old Wood could soon step away from the investing world.
- 09/30/2022
|
Cathie Wood's Ark Invest Adds $7M Of Bitcoin-Focused Block Shares, Also Picks Up Some CareDx Stock
- Cathie Wood-led Ark Investment Management has bought over 100,000 shares of Jack Dorsey's Block Inc (NYSE: SQ), valued at over $6.9 million based on Wednesday's closing price.
- 09/14/2022
|
CareDx (CDNA) – Cathie Wood's Ark Invest Adds $3M In CareDx Shares Despite Bleak Q2 Results
- Cathie Wood-led Ark Investment Management loaded up on 153,917 shares of precision medicine company CareDx Inc (NASDAQ: CDNA), via the ARK Genomic Revolution ETF (NYSE: ARKG
- 08/30/2022
|
CareDx: Best Near Cap-Gain Health Diagnostics Prospect Say Market Makers
- Which of the healthcare diagnostic services producers is now a better buy to help build your portfolio's near-term capital value? Near-term only, repetition provides long term. Find out here what the best-informed, big-$ investors now think likely to happen (good and bad) in the next 3+ months to prices of several stocks now seen attractively priced.
- 08/08/2022
|
CareDx, Inc. (CDNA) CEO Reg Seeto on Q2 2022 Results - Earnings Call Transcript
- CareDx, Inc. (NASDAQ:CDNA ) Q2 2022 Results Conference Call August 4, 2022 4:30 PM ET Company Participants Ian Cooney - VP, IR Reg Seeto - CEO Abhishek Jain - Interim CFO Conference Call Participants Andrew Cooper - Raymond James Alex Nowak - Craig-Hallum Capital Group Brandon Couillard - Jefferies Jacob Johnson - Stephens Yi Chen - H.C. Wainwright E.V.
- 08/07/2022
|
CareDx, Inc (CDNA) CEO Reg Seeto on Q1 2022 Results - Earnings Call Transcript
- CareDx, Inc (NASDAQ:CDNA ) Q1 2022 Earnings Conference Call May 5, 2022 4:30 PM ET Company Participants Ian Cooney - VP of IR Reg Seeto - CEO Ankur Dhingra - CFO Conference Call Participants Alex Nowak - Craig-Hallum Capital Andrew Cooper - Raymond James Mason Carrico - Stephens Inc. Operator Good day, and welcome to the CareDx First Quarter 2022 Earnings Conference Call. All participants will be in listen-only mode.
- 05/05/2022
|
CareDx (CDNA) Reports Q1 Loss, Tops Revenue Estimates
- CareDx (CDNA) delivered earnings and revenue surprises of -225% and 1%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
- 05/05/2022
|
These Charts Explain Why I'm Holding This Healthcare Company
- Transplants are in high demand; this company is making the process of getting one smoother.
- 04/29/2022
|
CareDx to Report First Quarter 2022 Financial Results
- SOUTH SAN FRANCISCO, Calif., April 27, 2022 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients – today announced it will report financial results for the first quarter 2022 after market close on Thursday, May 5, 2022. Company management will host a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
- 04/27/2022
|
CareDx, Inc (CDNA) CEO Reg Seeto on Q4 2021 Results - Earnings Call Transcript
- CareDx, Inc (CDNA) CEO Reg Seeto on Q4 2021 Results - Earnings Call Transcript
- 02/24/2022
|
CareDx to Report Fourth Quarter and Full Year 2021 Financial Results
- SOUTH SAN FRANCISCO, Calif., Feb. 17, 2022 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients – today announced it will report financial results for the fourth quarter and full year 2021 after market close on Thursday, February 24, 2022. Company management will host a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
- 02/17/2022
|
CareDx To Participate In Upcoming Conferences
- SOUTH SAN FRANCISCO, Calif., Feb. 03, 2022 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that the Company will participate in the BTIG Virtual MedTech, Digital Health, Life Science & Diagnostic Tools Conference and the Raymond James 43rd Annual Institutional Investors Conference.
- 02/03/2022
|
CareDx Stock (CDNA): Why The Price Surged Today
- The stock price of CareDx, Inc. (Nasdaq: CDNA) increased by 18.48% in the most recent trading session. This is why it happened.
- 01/10/2022
|
CareDx: Short-Term Headwinds Will Pass, Longer-Term High Growth Investment Case Remains
- Although CareDx (CDNA) recently received inquiries from the DOJ and SEC, the longer-term investment case remains intact. CDNA has only begun to scratch the surface on its total market opportunity and the company is pursuing multiple growth strategies that should keep sales increasing at a high rate.
- 01/04/2022
|
Bear Of The Day:CareDX
- This stock has beaten the Zacks Consensus Estimate in each of the last four quarters but it has fallen to the lowest Zacks Rank.
- 12/01/2021
|
CareDx To Participate in Upcoming Conferences
- SOUTH SAN FRANCISCO, Calif., Nov. 15, 2021 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, announced today the Company will participate in the 12th Annual Jefferies London Healthcare Conference and the 4th Annual Evercore ISI HealthCONx Conference.
- 11/15/2021
|
7 Stocks to Buy in November in Light of Their October Dip
- October was a good month in the markets. It won't be easy to find stocks to buy on the dip.
- 11/15/2021
|
Why Cathie Wood Is Buying Beaten-Down CareDx
- Should you follow the internet's favorite stock picker into this tumbling diagnostics stock?
- 11/06/2021
|
Why Are CareDx Shares Slumping Despite Q3 Earnings Beat?
- CareDx Inc (NASDAQ: CDNA) reported Q3 revenues rose 42% Y/Y to $75.6 million, beating the consensus of $74.05 million. The increase was driven mainly by a 46% increase in testing service revenues to $66.5 million.
- 10/29/2021
|
Why CareDx Stock Is Falling Today Despite a Positive Earnings Call
- Third-quarter 2021 results were terrific, but the disclosure of two federal investigations isn't sitting well with investors.
- 10/29/2021
|
CareDx, Inc. (CDNA) CEO Reg Seeto on Q3 2021 Results - Earnings Call Transcript
- CareDx, Inc. (CDNA) CEO Reg Seeto on Q3 2021 Results - Earnings Call Transcript
- 10/28/2021
|
CareDx (CDNA) Q3 Earnings and Revenues Beat Estimates
- CareDx (CDNA) delivered earnings and revenue surprises of 133.33% and 1.82%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
- 10/28/2021
|
CareDx to Report Third Quarter 2021 Financial Results
- SOUTH SAN FRANCISCO, Calif., Oct. 14, 2021 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced it will report financial results for the third quarter 2021 after market close on Thursday, October 28, 2021. Company management will host a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
- 10/14/2021
|
AlloSure, the First dd-cfDNA in Heart and Kidney Transplantation, Launches for Lung Transplant Patients
- AlloSure Significantly Improves Management of High-Risk Lung Transplant Patients AlloSure Significantly Improves Management of High-Risk Lung Transplant Patients
- 10/12/2021
|
CareDx Extends Leadership in Multimodality Transplant Care with KidneyCare Validation Publication
- Multicenter Study Validates AlloMap and Demonstrates the Complementary Value with AlloSure for Detecting Rejection Multicenter Study Validates AlloMap and Demonstrates the Complementary Value with AlloSure for Detecting Rejection
- 09/30/2021
|
CareDx Continues to Fight for Innovation in Transplantation
- False Advertising Lawsuit Against Natera is Set to Go to Trial
- 09/28/2021
|
CareDx Presents Latest Data on AlloSeq Portfolio at ASHI 2021
- AlloSeq to be featured in 8 scientific abstracts at ASHI conference AlloSeq to be featured in 8 scientific abstracts at ASHI conference
- 09/27/2021
|
COVID 19 Stocks -- Vaccines, Diagnostics, or Treatments?
- Which subset of the COVID-19 healthcare market will outperform over the next year?
- 08/31/2021
|
CareDx Showcases Leadership in Global Transplantation at ESOT 2021
- CareDx announces the launch of AlloSeq cfDNA Research Service and demonstrates global leadership at ESOT with six abstracts and a symposium CareDx announces the launch of AlloSeq cfDNA Research Service and demonstrates global leadership at ESOT with six abstracts and a symposium
- 08/26/2021
|
CareDx: A Near-Term Capital-Gainer Among Healthcare Diagnostics, Say Market-Makers
- Why so reliant on M-Ms? Because they have the big-volume-trade clients who need their quick, quiet knowledgeable assistance while managing multi-billion-$ stock portfolios.
- 08/15/2021
|
CareDx, Inc. (CDNA) CEO Reg Seeto on Q2 2021 Results - Earnings Call Transcript
- CareDx, Inc. (CDNA) CEO Reg Seeto on Q2 2021 Results - Earnings Call Transcript
- 07/30/2021
|
CareDx (CDNA) Beats Q2 Earnings and Revenue Estimates
- CareDx (CDNA) delivered earnings and revenue surprises of 120.00% and 9.07%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
- 07/29/2021
|
CareDx Launches ACROBAT Study to Potentially Change Care Paradigm for Stem Cell Transplant Patients
- ACROBAT is the prospective multi-center study of AlloHeme, to study the potential of relapse surveillance for stem cell transplant patients ACROBAT is the prospective multi-center study of AlloHeme, to study the potential of relapse surveillance for stem cell transplant patients
- 07/26/2021
|
Apple, Array Tech, Vertex Pharma and More Tuesday Afternoon Analyst Calls
- With the trading day more than halfway over, the broad markets were rallying after the carnage on Monday.
- 07/20/2021
|
CareDx to Report Second Quarter 2021 Financial Results
- SOUTH SAN FRANCISCO, Calif., July 15, 2021 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced it will report financial results for the second quarter 2021 after market close on Thursday, July 29, 2021. Company management will host a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
- 07/15/2021
|
CareDx Transplant Patient App, AlloCare, Expands Access to the Majority of Transplant Patients
- AlloCare launches in Android Play Store, and is now available on both iOS and Android for all transplant patients AlloCare launches in Android Play Store, and is now available on both iOS and Android for all transplant patients
- 07/01/2021
|
CareDx to Participate in Raymond James 2021 Human Health Innovation Conference
- SOUTH SAN FRANCISCO, Calif., June 16, 2021 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, announced today the Company plans to participate in the Raymond James 2021 Human Health Innovation Conference.
- 06/16/2021
|
CareDx congratulates Hannah Valantine for her State of the Art Lecture at ATC on Transplant Equity
- Valantine's ATC Presentation Highlights the Role of AlloMap and AlloSure on Inclusive Research and Development Valantine's ATC Presentation Highlights the Role of AlloMap and AlloSure on Inclusive Research and Development
- 06/09/2021
|
CareDx Presents Landmark KOAR-1000 Data, Demonstrating Higher 1-Year Graft Survival and Reduction in Biopsies through ARTS Surveillance
- KOAR is the largest prospective validation study on AlloSure surveillance with over 1,500 patients enrolled KOAR is the largest prospective validation study on AlloSure surveillance with over 1,500 patients enrolled
- 06/07/2021
|
CareDx Presents Groundbreaking AlloSure® Data at the 2021 American Transplant Congress
- Transplant physicians to present 40 scientific abstracts, plus two symposia to highlight latest data from multi-center studies on clinical utility of AlloSure Transplant physicians to present 40 scientific abstracts, plus two symposia to highlight latest data from multi-center studies on clinical utility of AlloSure
- 06/04/2021
|
CareDx Advances Artificial Intelligence in Transplantation
- Partnership with OrganX to develop decision support systems Partnership with OrganX to develop decision support systems
- 06/03/2021
|
APA, Bloom Energy, NetApp and More Thursday Afternoon Analyst Calls
- With the trading day about halfway over, the markets were sliding, with the tech sector getting the worst of it.
- 06/03/2021
|
CareDx Starts Enrollment in MAPLE, a Multi-modal, Multi-center, Prospective Study of LiverCare
- Study to demonstrate utility of LiverCare post-transplant surveillance for liver transplant recipients Study to demonstrate utility of LiverCare post-transplant surveillance for liver transplant recipients
- 06/01/2021
|
CareDx Announces Strategic Minority Investment in Miromatrix
- Participation in Series C and Research Partnership to Advance Development of Bioengineered Transplantable Organs Participation in Series C and Research Partnership to Advance Development of Bioengineered Transplantable Organs
- 05/28/2021
|
CareDx: The Market Leader In Organ Transplant Diagnostic Solutions/Software, With Strong Growth Prospects
- CareDx, Inc (CDNA) is dominating the organ transplant diagnostic solutions market, growing at 40% annually.
- 05/24/2021
|
CareDx to Participate in AAKP and George Washington University Global Summit on Kidney Disease Innovations
- CareDx to share innovations in donor-derived cell-free DNA (dd-cfDNA) and patient engagement CareDx to share innovations in donor-derived cell-free DNA (dd-cfDNA) and patient engagement
- 05/13/2021
|
This Under-the-Radar Healthcare Company Quietly Surged During the Pandemic
- CareDx just posted 76% year-over-year revenue growth for the first quarter and raised its 2021 guidance.
- 05/07/2021
|
CareDx, Inc.'s (CDNA) CEO Reginald Seeto on Q1 2021 Results - Earnings Call Transcript
- CareDx, Inc.'s (CDNA) CEO Reginald Seeto on Q1 2021 Results - Earnings Call Transcript
- 05/05/2021
|
CareDx (CDNA) Q1 Earnings and Revenues Surpass Estimates
- CareDx (CDNA) delivered earnings and revenue surprises of 1500.00% and 10.91%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
- 05/05/2021
|
ARK Genomic Revolution ETF: Value Realization Will Take Time
- ARK Genomic Revolution ETF: Value Realization Will Take Time
- 05/03/2021
|
CareDx to Present New Heart Transplant Data at the International Society for Heart and Lung Transplantation Annual Meeting
- Renowned transplant clinicians to present 15 heart abstracts at ISHLT Renowned transplant clinicians to present 15 heart abstracts at ISHLT
- 04/23/2021
|
Palmetto MolDx Issues Foundational Coverage for Molecular Testing in Solid Organ Allograft Rejection
- Current Medicare coverage for CareDx services remains unchanged under the new universal coverage policy Current Medicare coverage for CareDx services remains unchanged under the new universal coverage policy
- 04/22/2021
|
CareDx to Debut Multicenter Data on AlloSure® Lung, an Analytically and Clinically Validated Biomarker of Graft Injury for Lung Transplant Patients
- Leading transplant clinicians to present data in seven abstracts at International Society of Heart and Lung Transplantation Annual Meeting Leading transplant clinicians to present data in seven abstracts at International Society of Heart and Lung Transplantation Annual Meeting
- 04/22/2021
|
CareDx to Report First Quarter 2021 Financial Results
- SOUTH SAN FRANCISCO, Calif., April 21, 2021 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced it will report financial results for the first quarter 2021 after market close on Wednesday, May 5, 2021. Company management will host a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
- 04/21/2021
|
CareDx Showcases Transplantation Innovation and Leadership in Europe at EFI 2021
- Virtual Events to Highlight New Data and AlloSeq Solutions for European Labs and Clinicians Virtual Events to Highlight New Data and AlloSeq Solutions for European Labs and Clinicians
- 04/20/2021
|
CareDx to Present at UNOS Transplant Management Forum
- Company to showcase its latest integrated solutions for improving care across the whole transplant journey Company to showcase its latest integrated solutions for improving care across the whole transplant journey
- 04/16/2021
|
CareDx Announces New HLA Typing Service Offering for Research Purposes
- Initial projects underway for global pharmaceutical company Initial projects underway for global pharmaceutical company
- 04/08/2021
|
CareDx to Participate in National Kidney Foundation 2021 Spring Clinical Meetings
- CareDx to Host Virtual Exhibitor Showcase and Continuing Medical Education Program CareDx to Host Virtual Exhibitor Showcase and Continuing Medical Education Program
- 04/05/2021
|
CareDx Enhances Leadership Team with Key Appointments
- CareDx Builds for the Future by Investing in Talent CareDx Builds for the Future by Investing in Talent
- 03/31/2021
|
CareDx Names Ankur Dhingra as New Chief Financial Officer
- SOUTH SAN FRANCISCO, Calif., March 11, 2021 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, announced the appointment of Ankur Dhingra as the company's new Chief Financial Officer (CFO) effective March 25, 2021. As CFO, Ankur will lead CareDx's global finance organization including treasury, tax, and other corporate functions, and report directly to President and Chief Executive Officer Reg Seeto.
- 03/11/2021
|
Like Guardant Health? You'll Love CareDx
- This under-the-radar diagnostics company is thriving yet reasonably priced.
- 03/03/2021
|
CareDx, Inc. (CDNA) CEO Reginald Seeto on Q4 2020 Results - Earnings Call Transcript
- CareDx, Inc. (CDNA) CEO Reginald Seeto on Q4 2020 Results - Earnings Call Transcript
- 02/24/2021
|
CareDx Reports Fourth Quarter and Full Year 2020 Results
- SOUTH SAN FRANCISCO, Calif., Feb. 24, 2021 (GLOBE NEWSWIRE) -- CareDx, Inc. (NASDAQ: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today reported financial results for the fourth quarter and full year ended December 31, 2020.
- 02/24/2021
|
CareDx (CDNA) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release
- CareDx (CDNA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 02/17/2021
|
CareDx to Report Fourth Quarter and Full Year 2020 Financial Results
- SOUTH SAN FRANCISCO, Calif., Feb. 12, 2021 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced it will report financial results for the fourth quarter and full year 2020 after market close on Wednesday, February 24, 2021. Company management will host a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
- 02/12/2021
|
CareDx to to Participate in Upcoming BTIG Virtual MedTech, Digital Health, Life Science & Diagnostic Tools Conference
- SOUTH SAN FRANCISCO, Calif., Feb. 10, 2021 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced that the Company will participate in the BTIG Virtual MedTech, Digital Health, Life Science & Diagnostic Tools Conference.
- 02/10/2021
|
CareDx Showcases Cellular Transplantation and Therapy Portfolio at TCT
- CareDx and Atara Biotherapeutics' AlloCell Partnership Highlighted in Poster Presentation at Upcoming TCT Meeting CareDx and Atara Biotherapeutics' AlloCell Partnership Highlighted in Poster Presentation at Upcoming TCT Meeting
- 02/05/2021
|
CareDx Announces Closing of Public Offering of Common Stock
- SOUTH SAN FRANCISCO, Calif., Jan. 25, 2021 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced the closing of its previously announced public offering of 1,923,077 shares of its common stock at a public offering price of $91.00 per share. In addition, CareDx has granted the underwriters a 30-day option to purchase up to 288,461 additional shares of its common stock. The net proceeds to CareDx from the offering are expected to be approximately $164.0 million, after deducting underwriting discounts and commissions and estimated offering expenses.
- 01/25/2021
|
CareDx Announces Pricing of Public Offering of Common Stock
- SOUTH SAN FRANCISCO, Calif., Jan. 20, 2021 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced the pricing of an underwritten public offering of 1,923,077 shares of its common stock at a public offering price of $91.00 per share. The gross proceeds to CareDx from this offering, before deducting underwriting discounts and commissions and offering expenses, are expected to be $175,000,007. In addition, CareDx has granted the underwriters a 30 day option to purchase up to 288,461 additional shares of its common stock offered in the public offering on the same terms and conditions. The offering is expected to close on or about January 25, 2021, subject to the satisfaction of customary closing conditions.
- 01/20/2021
|
CareDx Announces Proposed Public Offering of Common Stock
- SOUTH SAN FRANCISCO, Calif., Jan. 19, 2021 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced that it intends to offer and sell, subject to market and other conditions, up to $175.0 million of shares of its common stock in an underwritten public offering. CareDx also expects to grant the underwriters of the offering a 30 day option to purchase up to an additional $26.25 million of shares of its of common stock offered in the public offering on the same terms and conditions. All of the shares will be offered and sold by CareDx.
- 01/19/2021
|
CareDx Agrees to Acquire TransChart and Expands EMR Connectivity to Over 90 Centers
- Acquisition will build on CareDx's digital capabilities and continue deepening the moat with transplant centers Acquisition will build on CareDx's digital capabilities and continue deepening the moat with transplant centers
- 01/08/2021
|
CareDx Transplant Leadership Showcased at ASTS 2021
- CareDx Shares Latest Clinical Data at the 21st Annual American Society of Transplant Surgeons Digital Winter Symposium CareDx Shares Latest Clinical Data at the 21st Annual American Society of Transplant Surgeons Digital Winter Symposium
- 01/08/2021
|
CareDx's AlloSeq HCT Wins Tender for French Stem Cell Transplant Patient Surveillance
- CareDx wins a 2-year competitive tender with the French National Blood Service, Établissement Français du Sang CareDx wins a 2-year competitive tender with the French National Blood Service, Établissement Français du Sang
- 01/04/2021
|
CareDx: Stock To Achieve Significant Long-Term Growth
- CareDx offers organ testing products that are non-invasive alternatives to more invasive traditional tests. The organ transplant market is expected to grow through 2027, creating a tailwind for CareDx.
- 01/03/2021
|
5 Stocks With Unstoppable Growth to Buy in 2021
- Investing in stocks which have outpaced the market in 2020, defying the impacts of the COVID-19 outbreak, and have the potential for greater returns in 2021 is advisable.
- 12/30/2020
|
4 MedTech Stocks Up More Than 100% in 2020 With Room to Run
- We discuss four MedTech stocks, CDNA, FLGT, OMI and QDEL that more than doubled in 2020, and are poised to maintain market beating momentum in 2021 on strong fundamentals.
- 12/23/2020
|
CareDx Celebrates the Long-Awaited Passage of the Immuno Bill
- Partners with large transplant coalition to expand access to lifesaving medications for kidney transplant patients Partners with large transplant coalition to expand access to lifesaving medications for kidney transplant patients
- 12/22/2020
|
CareDx's (CDNA) Shares March Higher, Can It Continue?
- As of late, it has definitely been a great time to be an investor in CareDx (CDNA).
- 12/21/2020
|
4 Top Medical Services Stocks to Beat COVID-19 Resurgence Crisis
- The COVID-19 crisis has drastically transformed the fortune of the medical services industry. The industry has been witnessingsignificant demand for telemedicine-focused online medical services.
- 12/17/2020
|
CareDx (CDNA) Is Up 12.28% in One Week: What You Should Know
- Does CareDx (CDNA) have what it takes to be a top stock pick for momentum investors? Let's find out.
- 11/26/2020
|
CareDx to Participate in Upcoming Piper Sandler 32nd Annual Virtual Healthcare Conference
- SOUTH SAN FRANCISCO, Calif., Nov. 25, 2020 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced that the Company will participate in the upcoming Piper Sandler 32nd Annual Virtual Healthcare Conference.
- 11/25/2020
|
CareDx Receives Medicare Reimbursement Pricing for AlloSure Heart
- SOUTH SAN FRANCISCO, Calif., Nov. 17, 2020 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, announced it has received final reimbursement pricing of $2,753 from Palmetto MolDx for AlloSure Heart.
- 11/17/2020
|
New Publication Shows CareDx's AlloSure May Be Effective for Monitoring BK Virus in Transplant Patients
- Research from Johns Hopkins , U niversity of Maryland, and Cedars Sinai Shows AlloSure May Signal BK Virus Progression in Transplant Patients
- 11/06/2020
|
CareDx Joins National Kidney Foundation in Virtual Walk for Kidney Patients
- CareDx's Chief Marketing Officer Sasha King is the Chair for the Upcoming Pacific Northwest Virtual Kidney Walk CareDx's Chief Marketing Officer Sasha King is the Chair for the Upcoming Pacific Northwest Virtual Kidney Walk
- 11/06/2020
|
CareDx, Inc. (CDNA) CEO Peter Maag on Q3 2020 Results - Earnings Call Transcript
- CareDx, Inc. (CDNA) CEO Peter Maag on Q3 2020 Results - Earnings Call Transcript
- 11/01/2020
|
CareDx, Inc's (CDNA) CEO Peter Maag On Q3 2020 Results - Quick Version Earnings Call Transcript
- CareDx, Inc's (CDNA) CEO Peter Maag On Q3 2020 Results - Quick Version Earnings Call Transcript
- 10/29/2020
|
Peter Maag Appointed Executive Chairman of the Board of Directors of CareDx; Reginald Seeto Appointed President and CEO
- SOUTH SAN FRANCISCO, Calif., Oct. 29, 2020 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced that effective November 1, 2020, Peter Maag, current Chairman and Chief Executive Officer, will assume the role of Executive Chairman of the Board of Directors, and Reginald Seeto, currently President and Chief Business Officer, will assume the role of President and Chief Executive Officer and will join the CareDx Board of Directors.
- 10/29/2020
|
CareDx Reports Third Quarter 2020 Results
- SOUTH SAN FRANCISCO, Calif., Oct. 29, 2020 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today reported financial results for the quarter ended September 30, 2020.
- 10/29/2020
|
A Peek Into The Markets: US Stock Futures Climb On Stimulus Hopes
- Pre-open movers
U.S. stock futures traded higher in early pre-market trade. The Dow Jones jumped over 500 points in the previous session after President Donald Trump supported...
- 10/08/2020
|
Global Transplant Diagnostics Market Trajectory & Analytics, 2020-2027: U.S. Market is Estimated at $970.2 Million, While China is Forecast to Grow at 9.4% CAGR - ResearchAndMarkets.com
|
Hair Transplant Services Market Global Industry Analysis, Size, Share, Growth, Trends And Forecast 2018 – 2025
- WiseGuyReports.com Publish A New Market Research Report on –“ Hair Transplant Services Market Global Industry Analysis, Size, Share, Growth, Trends And Forecast
- 09/22/2020
|
Mutual of America Capital Management LLC Purchases 19,756 Shares of CareDx Inc (NASDAQ:CDNA)
- Mutual of America Capital Management LLC lifted its stake in shares of CareDx Inc (NASDAQ:CDNA) by 32.4% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 80,657 shares of the company’s stock after buying an additional 19,756 shares during the quarter. Mutual of America […]
- 08/22/2020
|
Did Hedge Funds Make The Right Call On CareDx, Inc. (CDNA)?
- How do you pick the next stock to invest in? One way would be to spend days of research browsing through thousands of publicly traded companies. However, an easier way is to look at the stocks that smart money investors are collectively bullish on. Hedge funds and other institutional investors usually invest large amounts of […]
- 08/12/2020
|
CareDx Inc (NASDAQ:CDNA) CEO Sells $478,304.16 in Stock
- CareDx Inc (NASDAQ:CDNA) CEO Peter Maag sold 13,008 shares of the company’s stock in a transaction dated Wednesday, August 5th. The shares were sold at an average price of $36.77, for a total value of $478,304.16. Following the completion of the sale, the chief executive officer now owns 425,134 shares of the company’s stock, valued […]
- 08/11/2020
|
The Daily Biotech Pulse: FDA Nod For GlaxoSmithKline, Bristol-Myers Squibb Earnings, Acutus Medical IPO
- Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 5)
ABIOMED, Inc. (NASDAQ: ABMD)
Aerpio Pharmaceuticals Inc (NASDAQ: ARPO) (announced a U.S. government grant for a...
- 08/06/2020
|
How Does CareDx's (NASDAQ:CDNA) CEO Pay Compare With Company Performance?
- This article will reflect on the compensation paid to Peter Maag who has served as CEO of CareDx, Inc (NASDAQ:CDNA...
- 08/05/2020
|
CareDx Inc (CDNA) Q2 2020 Earnings Call Transcript
- Earlier today, CareDx released financial results for the quarter ended June 30, 2020. Peter Maag, Chief Executive Officer; and Michael Bell, Chief Financial Officer, will host this afternoon's call. Before we get started, I would like to remind everyone that management will be making statements during this call that include forward-looking statements within the meaning of the federal securities laws, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.
- 08/05/2020
|
CareDx (CDNA) Q2 Earnings and Revenues Surpass Estimates
- CareDx (CDNA) delivered earnings and revenue surprises of 166.67% and 17.69%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
- 08/04/2020
|
CareDx Reports Second Quarter 2020 Results
- Patient-focused during COVID-19 pandemic and succeedingSOUTH SAN FRANCISCO, Calif., Aug. 04, 2020 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today reported financial results for the quarter ended June 30, 2020. Second Quarter 2020 and Recent Highlights: * Achieved total revenue of $41.8 million for the three months ended June 30, 2020, increasing 33% year-over-year * Provided over 17,100 AlloSure Kidney and AlloMap Heart patient results, with over 40% originating from RemoTraC and mobile phlebotomy * Recorded first-ever AlloCell revenue from a cell therapy partnership * Completed successful public offering raising $134.6 million in net proceeds, increasing cash and cash equivalents to $211.4 million“Throughout this challenging time, our team at CareDx successfully executed across our initiatives and never wavered from our commitment to improving the lives of transplant patients. Our performance in the second quarter, highlighted by strong growth and robust results from RemoTraC, is a testament to our patient-focus and dedication,” said Peter Maag, CareDx Chairman and Chief Executive Officer. “As we look to the second half of this year, while uncertainty continues, what remains clear is the dedication of our team, our ability to navigate through this time and our confidence to be able to continue to deliver durable long-term operational growth.”Second Quarter 2020 Financial ResultsRevenue for the three months ended June 30, 2020 was $41.8 million, compared with $31.5 million in the second quarter of 2019. Testing services revenue for the second quarter was $36.3 million, compared with $25.7 million in the same period of 2019. Product revenue in the three months ended June 30, 2020 was $3.3 million, compared to $4.6 million in the same period of 2019. Digital and other revenue for the second quarter 2020 was $2.2 million, compared to $1.2 million in the same period of 2019.For the second quarter of 2020, the net loss was $6.6 million compared to a net loss of $7.8 million in the same period of 2019. Diluted net loss per share was $0.15 in the second quarter of 2020, compared to a diluted net loss per share of $0.19 in the second quarter of 2019.Non-GAAP net income was $1.7 million in the second quarter of 2020 compared to $0.1 million non-GAAP net loss in the second quarter of 2019. Diluted non-GAAP net income per share was $0.04 in the second quarter of 2020, compared to a diluted non-GAAP net loss per share of $0.00 in the second quarter of 2019.Adjusted EBITDA for the second quarter of 2020 was a loss of $2.8 million, compared to an adjusted EBITDA gain of $0.1 million in the second quarter of 2019.Cash and cash equivalents were $211.4 million as of June 30, 2020.For additional information regarding non-GAAP financial measures discussed herein, please see “Use of Non-GAAP Financial Measures,” “Reconciliation of GAAP to Non-GAAP Financial Measures,” and “Reconciliation of GAAP to Non-GAAP Adjusted EBITDA Financial Measures” below.2020 GuidanceWhile CareDx experienced improved trends in the second quarter, due to the continued uncertainties with respect to the COVID-19 pandemic, CareDx will not be providing guidance at this time.About CareDxCareDx, Inc., headquartered in South San Francisco, California, is a leading precision medicine solutions company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. CareDx offers testing services, products, and digital healthcare solutions along the pre- and post-transplant patient journey, and is the leading provider of genomics-based information for transplant patients. For more information, please visit: www.CareDx.com.Forward-Looking StatementsThis press release includes forward-looking statements, including expectations regarding the achievement of our financial and operational goals and our prospects. These forward-looking statements are based upon information that is currently available to CareDx and its current expectations, speak only as of the date hereof, and are subject to numerous risks and uncertainties, including general economic and market factors, among others discussed in CareDx’s filings with the SEC, including the Annual Report on Form 10-K for the fiscal year ended December 31, 2019, filed by CareDx with the SEC on February 28, 2020, and the periodic reports that CareDx has subsequently filed with the SEC. Any of these may cause CareDx’s actual results, performance or achievements to differ materially and adversely from those anticipated or implied by CareDx’s forward-looking statements. CareDx expressly disclaims any obligation, except as required by law, or undertaking to update or revise any such forward-looking statements.Use of Non-GAAP Financial MeasuresCareDx has presented in this release certain financial information in accordance with U.S. Generally Accepted Accounting Principles (GAAP) and also on a non-GAAP basis, including non-GAAP net income, non-GAAP basic and diluted net income per share and adjusted EBITDA. We define non-GAAP net income and per share results as the GAAP net income and per share results excluding the impacts of stock-based compensation; changes in estimated fair value of warrants, derivative liabilities and contingent consideration; acquisition related impairment charges and amortization of intangible assets, purchase accounting adjustments and related tax effects; costs involved with completing an acquisition; amortization of debt discount; and certain other financing charges. We define adjusted EBITDA as non-GAAP net income/(loss) before net interest expense, income tax expense, depreciation and amortization, and other income and expense. We are presenting these non-GAAP financial measures to assist investors in assessing our operating results through the eyes of management and because we believe that these measures provide an additional tool for investors to use in comparing our core business operating results over multiple periods. Management believes this non-GAAP information is useful for investors, when considered in conjunction with CareDx's GAAP financial statements, because management uses such information internally for its operating, budgeting and financial planning purposes. Non-GAAP information is not prepared under a comprehensive set of accounting rules and should only be used to supplement an understanding of CareDx's operating results as reported under GAAP. These non-GAAP financial measures should not be considered in isolation from, or as a substitute for, financial information prepared in accordance with GAAP. These non-GAAP financial measures are not necessarily comparable to similarly-titled measures presented by other companies. A reconciliation between GAAP and non-GAAP financial information is provided immediately following the financial tables.Investor Relations ContactGreg Chodaczek 347-620-7010 investor@caredx.com CareDx, Inc. Condensed Consolidated Statements of Operations (Unaudited) (In thousands, except share and per share data) Three Months Ended June 30, Six Months Ended June 30, 2020 2019 2020 2019 Revenue: Testing services revenue $36,293 $25,677 $67,735 $47,195 Product revenue 3,291 4,593 7,986 9,026 Digital and other revenue 2,217 1,184 4,460 1,215 Total revenue 41,801 31,454 80,181 57,436 Cost of revenue 15,025 11,512 27,417 21,245 Gross profit 26,776 19,942 52,764 36,191 Operating expenses: Research and development 13,129 7,630 23,142 13,244 Sales and marketing 12,134 10,644 23,857 17,569 General and administrative 12,316 8,512 22,319 17,618 Total operating expenses 37,579 26,786 69,318 48,431 Loss from operations (10,803) (6,844) (16,554) (12,240) Other income (expense): Interest income, net 21 300 117 642 Change in estimated fair value of common stock warrant liability (664) (1,351) (1,069) (4,360) CARES Act Provider Relief Fund 4,813 — 4,813 — Other expense, net (255) (172) (318) (246) Total other income (expense) 3,915 (1,223) 3,543 (3,964) Loss before income taxes (6,888) (8,067) (13,011) (16,204) Income tax benefit 330 220 630 826 Net loss $(6,558) $(7,847) $(12,381) $(15,378) Net loss per share: Basic $(0.15) $(0.19) $(0.28) $(0.37) Diluted $(0.15) $(0.19) $(0.28) $(0.37) Weighted-average shares used to compute net loss per share: Basic 44,708,037 42,132,396 43,765,732 41,873,337 Diluted 44,708,037 42,132,396 43,765,732 41,873,337 CareDx, Inc.
- 08/04/2020
|
The Daily Biotech Pulse: Voyager, AbbVie End Collaboration, Thumbs Down For DBV's Peanut Allergy Patch, Tiziana Expedites COVID-19 Trial Plans
- Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 3)
ABIOMED, Inc. (NASDAQ: ABMD)
ALX Oncology Holdings Inc (NASDAQ: ALXO)
Annexon Inc (NASDAQ: ANNX)
Atossa...
- 08/04/2020
|
The Week Ahead In Biotech: Novavax Coronavirus Vaccine Readout, FDA Decisions And More Earnings
- Biotech stocks came under pressure in the week ended July 31 amid mixed earnings from the sector and some adverse clinical readouts.
COVID-19 news flow continued to pour in,...
- 08/02/2020
|
CareDx to Participate at the Canaccord Genuity 40th Annual Growth Conference
- SOUTH SAN FRANCISCO, Calif., July 30, 2020 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, announces today it will be participating in the Canaccord Genuity 40th Annual Growth Conference, scheduled to be held virtually August 11-13, 2020. CareDx’s management is scheduled to present on Wednesday, August 12, 2020, at 1:00 p.m. EDT. Interested parties may access a live audio webcast of the presentation by visiting the “Investors” section of the company’s website at investors.caredxinc.com. About CareDx CareDx, Inc., headquartered in South San Francisco, California, is a leading precision medicine solutions company focused on the discovery, development and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. CareDx offers testing services, products, and digital healthcare solutions along the pre- and post-transplant patient journey and is the leading provider of genomics-based information for transplant patients. For more information, please visit: www.CareDx.com.CONTACTS:CareDx, Inc. Sasha King Chief Marketing Officer 415-287-2393 sking@caredx.comInvestor Relations Greg Chodaczek 646-924-1769 investor@caredx.com
- 07/30/2020
|
3 Artificial Intelligence Stocks With Long-Term Narratives
- Artificial intelligence (AI) is a buzzword in tech these days. The term, which encompasses a range of technologies including machine learning and data analysis. The goal is to create systems that can perceive, learn, and reason in ways that mimic human capabilities. At its best, AI will allow machines to understand the gestalt of a situation and react accordingly, a capability that humans take for granted – but has tended to elude computer systems, which in their turn excel at analyzing minute details.A wide range of tech companies are working on AI systems; artificial intelligence holds the promise of real-time data analysis and situation monitoring, with the machines capable of handling routine decisions. While it hasn’t been achieved yet, the outlines of success are visible on the horizon.Every smart investor knows to keep his eyes on the horizon; that is, to plan every investment with long-range intentions. Just how long is up to the individual, but most investors agree that a move isn’t long-term unless it’s held for more than one year. Warren Buffett has famously said, “If you are not willing to own a stock for 10 years, do not even think about owning it for 10 minutes.”With this in mind, we used TipRanks' database to identify three AI stocks that have been highlighted by some of Wall Street’s best tech sector analysts. These are analysts with 5-star ratings, standing above their peers in accuracy and average returns – and they’ve tapped Artificial Intelligence as a tech segment for the long run. Veritone, Inc. (VERI)We’ll start with Veritone. This media tech company offers a cloud-based operating system for AI that uses machine learning to turn data into useful intelligence. The software allows users to process audio and video in real time, enhance analytics and research apps, reduce content review times, and streamline time spent on ‘low-value, high-effort’ tasks.The value of the product to the customers can be seen in the quarterly earnings trends and the share appreciation. The last six months – covering the worst of the global pandemic and economic recessionary pressures – have seen VERI’s earnings steadily improve and the share price rise to its best level in over two years. Earlier this month, Veritone showed its confidence by adjusting its Q2 revenue guidance upwards. The guidance, of $13.1 to $13.3 million, is well above the previous upper guide of $12.2 million.The share price has tracked the gains in revenue and earnings. The stock has more than doubled since the February/March market collapse, rising from $3.03 to $10.83 now. Patrick Walravens, writing from JMP Securities, was impressed by Veritone’s new revenue guidance, and reiterated his Buy rating on the stock. In his comments, he said, “Veritone seems to be gaining traction in its Government, Legal, and Compliance verticals as it experienced record bookings in the quarter… we believe the company is moving its cost structure in the right direction with recent cost-reduction initiatives and upgrades…”With his $17 price target, Walravens shows his own confidence that VERI will see 57% growth in the year ahead. (To watch Walravens’ track record, click here)Overall, VERI’s Moderate Buy analyst consensus rating is based on 4 Buys and just a single Sell. The stock’s current price is $11.80, and the average price target $16.25 suggests it has a 50% upside potential. Note that even the low-ball target estimate, of $15, is well above the current price. (See Veritone stock analysis on TipRanks)ZoomInfo Technologies (ZI)Next up is ZoomInfo, a marketing tech company. ZI offers the usual features and services that customers expect in digital marketing intelligence, including account management, data management, demand generation, and lead prospecting. The company’s AI cloud software is specifically designed to improve efficiency in these tasks, letting sellers get to the business of selling.ZoomInfo is a newly public company, having held its IPO just this past June. The opening was a success, with share prices almost doubling on the first day and nearly tripling in the first few trading sessions. Even now, after nearly two months during which the initial excitement waned and the glow came off the rose, the stock is still trading 88% above its initial price of $21.The strong IPO prompted SunTrust Robinson analyst Terry Tillman – who is rated in the top 10 of the TipRanks analyst database – to initiate coverage of the stock with a Buy rating. Tillman wrote of ZoomInfo, “We believe ZoomInfo represents a rare combination of strong top-line growth and best-in-class profitability. Its go-to-market (GTM) sales intelligence platform drives positive outcomes for B2B sales and marketing organizations - increasing leads, customers and revenue. Premium valuation justified owing to accelerating demand for GTM intelligence and company-specific drivers leading to significant revenue and profit upside.”Tillman’s Buy rating comes with a $60 price target, implying an impressive 51% upside potential. (To watch Tillman’s track record, click here)ZoomInfo holds a Moderate Buy rating from the analyst consensus. This is based on 16 reviews, including 7 Buys and 9 Holds. The stock’s $55.07 average price target suggests it has room for 32% growth from the $41.66 trading price this year. (See ZoomInfo stock analysis on TipRanks)CareDx (CDNA)Last on today’s list is a tech company in the health care sector. CareDx develops and delivers diagnostic surveillance systems for heart transplant patients. The company’s AI-powered software monitors patient progress in real time, allowing both the patient and the doctors to respond to any rapidly changing health issues in time to ensure a more successful outcome. The result is a novel development in long-term care.While CareDx’s products were originally designed to monitor heart transplants, the company has expanded. Its products now monitor most human organ transplants – including kidneys, an important niche, as the first successful organ transplant was conducted with a kidney, and this procedure is still among the most common of transplants. CareDx also has cloud-based AI systems to monitor lab results, and to connect digital implants with remote monitors.The company’s earnings have proven mostly immune to recent economic instability, as medical transplant patients and doctors cannot simply stop using the monitoring systems. And with a firm user base, the stock recovered well from the late-winter market crash. CDNA is up over 130% since bottoming out in March.Covering the stock for Piper Sandler, analyst Steven Mah wrote, “We believe CareDx has the broadest transplant care platform in the industry and we remain confident that it is well-positioned to protect and extend its first-mover advantage in both pre- and post-transplant patient management to drive long-term growth. In addition, we are encouraged by the resiliency of its essential tests and ability to operate in a COVID-19 environment.”Mah gives CDNA a Buy rating, along with a $54 price target that implies an upside of 66% for the next 12 months. (To watch Mah’s track record, click here)All in all, with 4 recent reviews on record, all Buys, CareDx has a unanimous Strong Buy rating from the analyst consensus. The stock is currently selling for $32.59, and the average price target, at $42.75, suggests a one-year upside of 31%. (See CareDx stock-price forecast on TipRanks)To find good ideas for tech stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.
- 07/25/2020
|
CareDx Inc (NASDAQ:CDNA) Shares Bought by Tiaa Fsb
- Tiaa Fsb grew its stake in shares of CareDx Inc (NASDAQ:CDNA) by 4.3% in the second quarter, according to its most recent filing with the SEC. The fund owned 77,491 shares of the company’s stock after acquiring an additional 3,170 shares during the period. Tiaa Fsb owned about 0.17% of CareDx worth $2,746,000 at the […]
- 07/17/2020
|
CareDx to Report Second Quarter 2020 Financial Results
- SOUTH SAN FRANCISCO, Calif., July 16, 2020 -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development and commercialization of.
- 07/16/2020
|
CareDx Chairman and CEO Peter Maag to Present at Global Kidney Innovations Summit
- SOUTH SAN FRANCISCO, Calif., July 15, 2020 -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of.
- 07/15/2020
|
AQR Capital Management LLC Sells 38,532 Shares of CareDx Inc (NASDAQ:CDNA)
- AQR Capital Management LLC trimmed its position in CareDx Inc (NASDAQ:CDNA) by 75.2% during the first quarter, HoldingsChannel reports. The institutional investor owned 12,706 shares of the company’s stock after selling 38,532 shares during the period. AQR Capital Management LLC’s holdings in CareDx were worth $277,000 at the end of the most recent reporting period. […]
- 07/11/2020
|
Zacks: Brokerages Expect CareDx Inc (NASDAQ:CDNA) Will Post Quarterly Sales of $35.52 Million
- Analysts expect CareDx Inc (NASDAQ:CDNA) to post $35.52 million in sales for the current quarter, according to Zacks Investment Research. Four analysts have made estimates for CareDx’s earnings. The highest sales estimate is $36.20 million and the lowest is $34.20 million. CareDx posted sales of $31.45 million during the same quarter last year, which suggests […]
- 07/04/2020
|
CareDx’s (CDNA) “Buy” Rating Reaffirmed at Piper Sandler
- Piper Sandler reaffirmed their buy rating on shares of CareDx (NASDAQ:CDNA) in a research note issued to investors on Monday morning, TipRanks reports. The firm currently has a $54.00 target price on the stock. A number of other brokerages also recently weighed in on CDNA. Zacks Investment Research downgraded shares of CareDx from a hold […]
- 06/30/2020
|
Hedge Funds Aren’t Crazy About CareDx, Inc. (CDNA) Anymore
- The financial regulations require hedge funds and wealthy investors that exceeded the $100 million equity holdings threshold to file a report that shows their positions at the end of every quarter. Even though it isn't the intention, these filings to a certain extent level the playing field for ordinary investors. The latest round of 13F […]
- 06/24/2020
|
New Kidney360 Publication Highlights CareDx’s AlloSure is Differentiated as the dd-cfDNA Test of Choice
- SOUTH SAN FRANCISCO, Calif., June 22, 2020 -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of.
- 06/22/2020
|
Deutsche Bank AG Boosts Stock Position in CareDx Inc (NASDAQ:CDNA)
- Deutsche Bank AG increased its holdings in CareDx Inc (NASDAQ:CDNA) by 0.8% during the 1st quarter, according to its most recent Form 13F filing with the SEC. The fund owned 237,795 shares of the company’s stock after purchasing an additional 1,781 shares during the period. Deutsche Bank AG owned approximately 0.54% of CareDx worth $5,191,000 […]
- 06/21/2020
|
CareDx Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares
- The option was granted in connection with the public offering of 3,906,250 shares of common stock at a public offering price of $32.00 per share, which closed on June 15, 2020. After giving effect to the exercise in full of the underwriters’ option, the total number of shares sold by CareDx in the public offering was 4,492,187 shares and the net proceeds to CareDx were approximately $134.7 million, after deducting underwriting discounts and commissions and estimated offering expenses.
- 06/18/2020
|
FDA Accepts Letter of Intent for iBox Scoring System as a Surrogate Endpoint in Pharmaceutical Clinical Trials
- SOUTH SAN FRANCISCO, Calif., June 18, 2020 -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of.
- 06/18/2020
|
CareDx Announces Closing of Public Offering of Common Stock
- In addition, CareDx has granted the underwriters a 30-day option to purchase up to 585,937 additional shares of its common stock. The net proceeds to CareDx from the offering are expected to be approximately $117.1 million, after deducting underwriting discounts and commissions and estimated offering expenses. CareDx intends to use the net proceeds from this offering for working capital and general corporate purposes.
- 06/15/2020
|
CareDx Announces Pricing of Public Offering of Common Stock
- SOUTH SAN FRANCISCO, Jun 10, 2020 (GLOBE NEWSWIRE via COMTEX) --
SOUTH SAN FRANCISCO, Calif., June 10, 2020 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA),...
- 06/11/2020
|
CareDx Announces Pricing of Public Offering of Common Stock
- The gross proceeds to CareDx from this offering, before deducting underwriting discounts and commissions and offering expenses, are expected to be $125,000,000. In addition, CareDx has granted the underwriters a 30 day option to purchase up to 585,937 additional shares of its common stock offered in the public offering on the same terms and conditions. CareDx intends to use the net proceeds from this offering for working capital and general corporate purposes.
- 06/11/2020
|
The Daily Biotech Pulse: Keytruda Setback For Merck, Denali Pulls The Plug On Neurological Asset
|
CareDx Reports $100M Common Stock Offering
|
CareDx Announces Proposed Public Offering of Common Stock
- CareDx also expects to grant the underwriters of the offering a 30-day option to purchase up to an additional $15.0 million of shares of its common stock offered in the public offering on the same terms and conditions. All of the shares will be offered and sold by CareDx. CareDx intends to use the net proceeds from this offering for working capital and general corporate purposes.
- 06/09/2020
|
Seven Bridges Selected by CareDx to Advance Its Transplant Care Solutions
- Seven Bridges, the industry-leading bioinformatics ecosystem provider, announced today a new partnership with CareDx, Inc. (Nasdaq: CDNA) supporting the CareDx AlloSure 3.0 workflow. CareDx is a leading precision medicine company focused on the discovery, development and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. The use of the Seven Bridges Platform and Automation products dramatically speed time to results by streamlining analysis workflows, minimizing the number of manual steps required to set up, run and conclude an analysis.
- 06/09/2020
|
CareDx Announces 2020 Annual Meeting of Stockholders to be Held as a Virtual Meeting
- Due to conditions associated with the impact of the Coronavirus pandemic (COVID-19), including restrictions on in-person gatherings, and in order to support the health and well-being of our stockholders and other meeting participants, CareDx’s 2020 Annual Meeting of Stockholders will be held in a virtual meeting format only. There is also no change to the items of business to be addressed at the Annual Meeting, which are described in CareDx’s proxy materials as previously distributed. As noted above, stockholders may not attend the Annual Meeting in person.
- 06/08/2020
|
Citigroup Inc. Acquires 41,867 Shares of CareDx Inc (NASDAQ:CDNA)
- Citigroup Inc. lifted its holdings in shares of CareDx Inc (NASDAQ:CDNA) by 500.1% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 50,238 shares of the company’s stock after purchasing an additional 41,867 shares during the period. Citigroup Inc. owned about 0.11% of […]
- 06/07/2020
|
State Street Corp Acquires 7,923 Shares of CareDx Inc (NASDAQ:CDNA)
- State Street Corp increased its holdings in CareDx Inc (NASDAQ:CDNA) by 0.3% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 2,572,766 shares of the company’s stock after buying an additional 7,923 shares during the quarter. State Street Corp owned 5.88% of […]
- 06/07/2020
|
CareDx to Participate at the Goldman Sachs Global Healthcare Conference
- SOUTH SAN FRANCISCO, Calif., June 04, 2020 -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development and commercialization of.
- 06/04/2020
|
CareDx to Present at the Jefferies Virtual Healthcare Conference
- SOUTH SAN FRANCISCO, Calif., May 28, 2020 -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development and commercialization of.
- 05/28/2020
|
CareDx Presents the Latest AlloSure Data in Virtual Meetings
- SOUTH SAN FRANCISCO, Calif., May 27, 2020 -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of.
- 05/27/2020
|
Caredx Inc (CDNA) CEO Peter Maag Sold $967,—…… of Shares
|
CareDx Reports Its AlloSeq Tx 17 Wins CE Mark Approval
|
CareDx's AlloSeq Tx 17 Awarded CE Mark Approval
- SOUTH SAN FRANCISCO, Calif., May 15, 2020 -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development and commercialization of.
- 05/15/2020
|
CareDx's AlloSeq Tx –7 Awarded CE Mark Approval
|
UPDATE: CareDx Will Become Exclusive Worldwide Commercialization Partner For Solid Organ Transplant-rejection Tests On Veracyte's Diagnostic Platform
|
CareDx And Veracyte Announce Exclusive Partnership For Transplant Rejection Testing On nCounter System
|
CareDx and Veracyte Announce Exclusive Partnership for Transplant Rejection Testing on nCounter System
- CareDx and Veracyte Announce Exclusive Partnership for Transplant Rejection Testing on nCounter System
- 05/14/2020
|
Gagnon Advisors, LLC Buys CareDx Inc, Profound Medical Corp, Enterprise Products Partners LP, ...
|
Caredx Inc (CDNA) CFO Michael Brian Bell Sold $–.7 million of Shares
|
CareDx Brings the Transplant Patient Community Together
- SOUTH SAN FRANCISCO, Calif., May 07, 2020 -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of.
- 05/07/2020
|
Redwood Investments, LLC Buys Horizon Therapeutics PLC, NovoCure, Tetra Tech Inc, Sells Funko ...
|
CareDx Collaborates With Weill Cornell Medicine To Lead Development And Commercialization Of UroMap
|
CareDx Collaborates with Weill Cornell Medicine to Lead the Development and Commercialization of UroMap
- SOUTH SAN FRANCISCO, Calif., May 05, 2020 -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of.
- 05/05/2020
|
Stocks Showing Market Leadership: Caredx Earns 91 RS Rating
|
Stocks Flashing Renewed Technical Strength: Caredx
|
Here's Why We're Not At All Concerned With CareDx's (NASDAQ:CDNA) Cash Burn Situation
- We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
- 05/02/2020
|
CareDx Inc (CDNA) Q1 2020 Earnings Call Transcript
- Earlier today, CareDx released financial results for the quarter ending March 31, 2020. Peter Maag, Chief Executive Officer; and Michael Bell, Chief Financial Officer, will host this afternoon's call.
- 05/01/2020
|
HC Wainwright & Co. Reiterates Buy on CareDx, Lowers Price Target to $40
|
H.C. Wainwright Keeps a Buy Rating on CareDx (CDNA)
- In a report released today, Yi Chen from H.C. Wainwright reiterated a Buy rating on CareDx (CDNA), with a price target of $40.00. The company's shares
- 05/01/2020
|
H.C. Wainwright Keeps a Buy Rating on CareDx (CDNA)
- In a report released today, Yi Chen from H.C. Wainwright reiterated a Buy rating on CareDx (CDNA – Research Report),
- 05/01/2020
|
Edited Transcript of CDNA earnings conference call or presentation 30-Apr-20 8:30pm GMT
- Q1 2020 CareDx Inc Earnings Call
- 05/01/2020
|
CareDx (NASDAQ:CDNA) Trading Down 5.5% Following Weak Earnings
- CareDx Inc (NASDAQ:CDNA)’s stock price was down 5.5% during mid-day trading on Thursday following a weaker than expected earnings announcement. The stock traded as low as $25.04 and last traded at $25.38, approximately 758,950 shares were traded during trading. A decline of 4% from the average daily volume of 790,105 shares. The stock had previously […]
- 05/01/2020
|
CareDx, Inc (CDNA) CEO Peter Maag on Q1 2020 Results - Earnings Call Transcript
- CareDx, Inc (NASDAQ:CDNA) Q1 2020 Earnings Conference Call April 30, 2020 4:30 PM ET Company Participants Greg Chodaczek - Head of Investor Relations Peter Maag
- 05/01/2020
|
CareDx (CDNA) Reports Break-Even Earnings for Q1
- CareDx (CDNA) delivered earnings and revenue surprises of -100.00% and 0.41%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
- 05/01/2020
|
CareDx: 1Q Earnings Snapshot
- SOUTH SAN FRANCISCO, Calif. (AP) _ CareDx Inc. (CDNA) on Thursday reported a loss of $5.8 million in its first quarter. On a per-share basis, the South San Francisco, California-based company said it had a loss of 14 cents. Earnings, adjusted for stock option expense and non-recurring costs, came to less than 1 cent on a per-share basis. The average estimate of three analysts surveyed by Zacks Investment Research was for earnings of 2 cents per share. The molecular diagnostics company posted revenue of $38.4 million in the period, which beat Street forecasts. Three analysts surveyed by Zacks expected $38.2 million. CareDx shares have climbed 18% since the beginning of the year. In the final minutes of trading on Thursday, shares hit $25.38, a fall of 8% in the last 12 months. _____ This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on CDNA at https://www.zacks.com/ap/CDNA
- 04/30/2020
|
CareDx: 1Q Earnings Snapshot
- SOUTH SAN FRANCISCO, Calif. (AP) _ CareDx Inc. (CDNA) on Thursday reported a loss of $5.8 million in its first quarter.
On a per-share basis, the South San Francisco, California-based company said it had a loss of 14 cents. Earnings, adjusted for sto
- 04/30/2020
|
CareDx Q1 EPS $0.00 Misses $0.03 Est., Sales $38.400M Beat $37.990M Estimate
|
CareDx Reports First Quarter 2020 Results
- SOUTH SAN FRANCISCO, Calif., April 30, 2020 -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of.
- 04/30/2020
|
The Daily Biotech Pulse: FDA Nod For GlaxoSmithKline, Hologic To Launch Coronavirus Test, Amarin's Strong Q1
- Here's a roundup of top developments in the biotech space over the last 24 hours.Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 29)• Arvinas Inc (NASDAQ: ARVN) • Biondvax Pharmaceuticals Ltd - ADR (NASDAQ: BVXV) • Bio-Rad Laboratories, Inc. Class A Common Stock(NYSE: BIO) • Capricor
- 04/30/2020
|
The Daily Biotech Pulse: FDA Nod For GlaxoSmithKline, Hologic To Launch Coronavirus Test, Amarin's Strong Q1
- Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs April 29)
• Arvinas Inc (NASDAQ...
- 04/30/2020
|
Notable earnings after Thursday's close
- AAPL, AEM, AJG, ALEX, AMGN, AMZN, ASGN, ATR, ATUS, BAND, BL, BLDR, BRKS, CDNA, CLGX, COG, COLM, CRY, CUZ, CXO, CXP, EBS, EGP, EIX, EMN, EXPO, FBHS, FHI, FMBI, FND, FTAI, FTV, FWRD, GILD, GLPI, HP, HTH
- 04/29/2020
|
CareDx Q1 2020 Earnings Preview
- CareDx (NASDAQ:CDNA) is scheduled to announce Q1 earnings results on Thursday, April 30th, after market close.The consensus EPS Estimate is $0.03 (-40.0% Y/Y) and the consensus Revenue Estimate is $38
- 04/29/2020
|
Perkins Capital Management Inc Buys Interpace Biosciences Inc, CareDx Inc, Gilead Sciences Inc, ...
|
CareDx Inc (NASDAQ:CDNA) Expected to Announce Earnings of -$0.02 Per Share
- Equities analysts expect CareDx Inc (NASDAQ:CDNA) to announce ($0.02) earnings per share for the current quarter, according to Zacks. Three analysts have made estimates for CareDx’s earnings, with the highest EPS estimate coming in at $0.05 and the lowest estimate coming in at ($0.15). CareDx reported earnings per share of $0.05 in the same quarter […]
- 04/28/2020
|
We’re Not Worried About CareDx’s (NASDAQ:CDNA) Cash Burn
- There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
- 04/27/2020
|
CareDx Engages European Lab Community in Virtual Meetings
- SOUTH SAN FRANCISCO, Calif., April 27, 2020 -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of.
- 04/27/2020
|
CareDx Engages European Lab Community in Virtual Meetings
- Leaders in HLA and transplant laboratory solutions will present at CareDx virtual symposiums originally planned for EFI
- 04/27/2020
|
CareDx Inc (NASDAQ:CDNA) Expected to Announce Quarterly Sales of $38.23 Million
- Wall Street analysts expect CareDx Inc (NASDAQ:CDNA) to post sales of $38.23 million for the current fiscal quarter, according to Zacks. Three analysts have issued estimates for CareDx’s earnings, with the lowest sales estimate coming in at $38.13 million and the highest estimate coming in at $38.35 million. CareDx posted sales of $25.98 million during […]
- 04/27/2020
|
CareDx Engages European Lab Community in Virtual Meetings
|
The Week Ahead In Biotech (April 26-May 2): Cancer Conference, Earnings News Flow In The Spotlight
- The week ended April 24 turned out to be an up-and-down one for biotech stocks, as the sector swayed along with the broader market. Two FDA approvals came through this week, with Immunomedics, Inc.'s (NASDAQ: IMMU) breast cancer drug snagging an FDA nod and Sanofi SA's (NASDAQ: SNY) meningococcal
- 04/26/2020
|
CareDx (NASDAQ:CDNA) Given Buy Rating at HC Wainwright
- CareDx (NASDAQ:CDNA)‘s stock had its “buy” rating reaffirmed by investment analysts at HC Wainwright in a note issued to investors on Friday, AnalystRatings.com reports. They currently have a $43.00 price target on the stock. HC Wainwright’s price target points to a potential upside of 72.83% from the stock’s previous close. A number of other research […]
- 04/26/2020
|
Head to Head Review: Anpac Bio-Medical Science (NASDAQ:ANPC) versus CareDx (NASDAQ:CDNA)
- Anpac Bio-Medical Science (NASDAQ:ANPC) and CareDx (NASDAQ:CDNA) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their institutional ownership, profitability, analyst recommendations, risk, dividends, earnings and valuation. Earnings and Valuation This table compares Anpac Bio-Medical Science and CareDx’s gross revenue, earnings per […]
- 04/26/2020
|
CareDx (CDNA) Receives a Buy from H.C. Wainwright
- H.C. Wainwright analyst Yi Chen reiterated a Buy rating on CareDx (CDNA) today and set a price target of $43.00. The company's shares closed last Thursday
- 04/24/2020
|
CareDx (CDNA) Receives a Buy from H.C. Wainwright
- H.C. Wainwright analyst
Yi Chen
reiterated a
Buy
rating on CareDx (
CDNA
–
Research Report
) today and set a price target of
$43.00
. The company’s shares closed last Thursday at $24.08.
According to
TipRanks.com
, Chen is a 4-star analyst with an av
- 04/24/2020
|
CareDx: A Robust Transplant Diagnostics Pick For 2020
- CareDx is targeting the medically essential stem cell and organ transplant market. The company has a robust financial profile. Investors, however, should be awa
- 04/23/2020
|
Earnings Preview: CareDx (CDNA) Q1 Earnings Expected to Decline
- CareDx (CDNA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 04/23/2020
|
Earnings Preview: CareDx (CDNA) Q1 Earnings Expected to Decline
- CareDx (CDNA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 04/23/2020
|
CareDx and Johns Hopkins Partner on AlloSure Lung Surveillance
- SOUTH SAN FRANCISCO, Calif., April 23, 2020 -- CareDx, Inc. (Nasdaq: CDNA) and Johns Hopkins University, announced today the launch of the ALARM (AlloSure Lung Allograft Remote.
- 04/23/2020
|
Caredx Getting Closer To Key Technical Measure
|
Fred Cohen Investor Profile: Portfolio & Exits | PitchBook
- Information on investments, active portfolio, exits, fund performance, dry powder, team and co-investors for Fred Cohen. Use the PitchBook Platform to explore the full profile.
- 04/22/2020
|
CareDx Presents New Heart and Lung Transplant Data in Virtual Meetings
- SOUTH SAN FRANCISCO, Calif., April 22, 2020 -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of.
- 04/22/2020
|
CareDx Presents New Heart and Lung Transplant Data in Virtual Meetings
- Leading transplant clinicians to present ten ISHLT accepted abstracts
- 04/22/2020
|
Bank of America Corp DE Sells 16,607 Shares of CareDx Inc (NASDAQ:CDNA)
- Bank of America Corp DE lowered its stake in CareDx Inc (NASDAQ:CDNA) by 19.1% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 70,371 shares of the company’s stock after selling 16,607 shares during the quarter. Bank of America Corp DE owned about 0.17% of […]
- 04/22/2020
|
CareDx Presents New Heart and Lung Transplant Data in Virtual Meetings
|
CareDx CEO Says Pandemic Proves Value Of Remote Transplant Monitoring System
- One outcome from the coronavirus pandemic could be the adoption of CareDx Inc (NASDAQ: CDNA)’s management platform for organ transplant patients.
“This...
- 04/21/2020
|
CareDx to Report First Quarter 2020 Financial Results
- SOUTH SAN FRANCISCO, Calif., April 21, 2020 -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development and commercialization of.
- 04/21/2020
|
CareDx to Report First Quarter —…—… Financial Results
|
CareDx Inc (NASDAQ:CDNA) Shares Sold by Geode Capital Management LLC
- Geode Capital Management LLC lowered its stake in CareDx Inc (NASDAQ:CDNA) by 1.9% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 550,209 shares of the company’s stock after selling 10,798 shares during the period. Geode Capital Management LLC’s holdings in CareDx […]
- 04/20/2020
|
Conestoga Capital Advisors LLC Has $574,000 Stock Holdings in CareDx Inc (NASDAQ:CDNA)
- Conestoga Capital Advisors LLC decreased its position in CareDx Inc (NASDAQ:CDNA) by 21.3% in the 1st quarter, HoldingsChannel reports. The fund owned 26,305 shares of the company’s stock after selling 7,100 shares during the period. Conestoga Capital Advisors LLC’s holdings in CareDx were worth $574,000 as of its most recent filing with the Securities & […]
- 04/19/2020
|
Analysts Offer Insights on Healthcare Companies: Bioxcel Therapeutics (BTAI), Madrigal Pharmaceuticals (MDGL) and CareDx (CDNA)
- There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Bioxcel Therapeutics (BTAI), Madrigal Pharmaceuticals
- 04/15/2020
|
Analysts Offer Insights on Healthcare Companies: Bioxcel Therapeutics (NASDAQ: BTAI), Madrigal Pharmaceuticals (NASDAQ: MDGL) and CareDx (NASDAQ: CDNA)
- There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Bioxcel Therapeutics
- 04/15/2020
|
Bank of New York Mellon Corp Boosts Position in CareDx Inc (NASDAQ:CDNA)
- Bank of New York Mellon Corp boosted its holdings in CareDx Inc (NASDAQ:CDNA) by 0.6% during the 4th quarter, HoldingsChannel reports. The institutional investor owned 262,783 shares of the company’s stock after purchasing an additional 1,476 shares during the quarter. Bank of New York Mellon Corp’s holdings in CareDx were worth $5,667,000 at the end […]
- 04/15/2020
|
CareDx Introduces AlloCell: Cell Therapy Surveillance
- AlloCell is a surveillance solution for patients who have received engineered-cell transplants for allogeneic cell therapy. Allogeneic cell therapy is a rapidly growing area of clinical development with research underway for applications in oncology, cardiovascular, neurological, autoimmune, and infectious disease.
- 04/14/2020
|
CareDx Introduces AlloCell: Cell Therapy Surveillance
|
CareDx Inc (NASDAQ:CDNA) Shares Sold by UBS Asset Management Americas Inc.
- UBS Asset Management Americas Inc. cut its holdings in CareDx Inc (NASDAQ:CDNA) by 12.0% in the 4th quarter, according to its most recent 13F filing with the SEC. The fund owned 29,770 shares of the company’s stock after selling 4,057 shares during the period. UBS Asset Management Americas Inc. owned 0.07% of CareDx worth $642,000 […]
- 04/13/2020
|
Nuveen Asset Management LLC Decreases Stock Position in CareDx Inc (NASDAQ:CDNA)
- Nuveen Asset Management LLC lessened its stake in CareDx Inc (NASDAQ:CDNA) by 7.9% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 911,367 shares of the company’s stock after selling 77,823 shares during the quarter. Nuveen Asset Management LLC’s holdings in […]
- 04/13/2020
|
Craig Hallum Cuts CareDx (NASDAQ:CDNA) Price Target to $42.00
- CareDx (NASDAQ:CDNA) had its price target decreased by Craig Hallum from $48.00 to $42.00 in a report published on Thursday, The Fly reports. Craig Hallum currently has a buy rating on the stock. Several other research analysts have also issued reports on CDNA. BidaskClub lowered CareDx from a buy rating to a hold rating in […]
- 04/12/2020
|
Is CareDx, Inc’s (NASDAQ:CDNA) CEO Paid Enough Relative To Peers?
- In 2012 Peter Maag was appointed CEO of CareDx, Inc (NASDAQ:CDNA). This report will, first, examine the CEO...
- 04/11/2020
|
Biohaven on go with study of vazegepant in COVID-19 as others take action amid the pandemic
- The FDA has signed off on a Phase 2 clinical trial evaluating intranasal administration of Biohaven Pharmaceutical Holding Company's (NYSE:BHVN) migraine med vazegepant, a calcitonin gene-related pept
- 04/09/2020
|
The Daily Biotech Pulse: FDA Nod For Pfizer, Vanda Forges Partnership For COVID-19 Drug Research, Neuronetics Pre-Announces Revenue Shortfall
- Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech stocks that hit 52-week highs April 8)
Keros Therapeutics Inc (...
- 04/09/2020
|
CareDx mobilizes 10,000 phlebotomists for home blood draws with RemoTraC CDNA;DGX
- CareDx mobilizes 10,000 phlebotomists for home blood draws with RemoTraC CDNA DGX
- 04/09/2020
|
Analysts Are Bullish on These Healthcare Stocks: CareDx (CDNA), Molecular Partners AG (MLLCF)
- There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on CareDx (CDNA) and Molecular Partners AG (MLLCF) with
- 04/09/2020
|
Analysts Are Bullish on These Healthcare Stocks: CareDx (CDNA), Molecular Partners AG (MLLCF)
- There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on CareDx (CDNA
- 04/09/2020
|
CareDx Mobilizes 10,000 Phlebotomists for Home Blood Draws of Transplant Patients with RemoTraC
- CareDx launched RemoTraC, a new service that provides home blood draws of routine transplant blood tests, on March 16 in response to the COVID-19 pandemic. Transplant patients are immunosuppressed and a high-risk group for COVID-19, prompting some to cancel or delay appointments for routine lab tests
- 04/09/2020
|
CareDx Reports Collaboration With Quest Diagnostics' ExamOne To Expand Mobile Phlebotomy Coverage Across US
|
CareDx Reports Preliminary First Quarter 2020 Revenue and Provides Business Update in Response to COVID-19 Pandemic
- In the quarter, the Company provided approximately 15,000 patient results, increasing 50% year-over-year. The preliminary information presented in this press release is based on CareDx’s current expectations and may be adjusted as a result of, among other things, completion of customary quarterly review procedures. "Despite the rapid onset of COVID-19 and stay-at-home orders, which has led to a slowdown in testing services volumes in recent weeks, I am very pleased with our first quarter performance," said Peter Maag, CareDx Chairman and Chief Executive Officer.
- 04/08/2020
|
Man Group plc Takes Position in CareDx Inc (NASDAQ:CDNA)
- Man Group plc purchased a new position in CareDx Inc (NASDAQ:CDNA) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund purchased 95,459 shares of the company’s stock, valued at approximately $2,059,000. Man Group plc owned approximately 0.22% of CareDx at the end of the most recent quarter. […]
- 04/08/2020
|
CareDx (NASDAQ:CDNA) Stock Price Down 6.3%
- CareDx Inc (NASDAQ:CDNA)’s stock price fell 6.3% on Tuesday . The company traded as low as $20.42 and last traded at $20.56, 689,641 shares changed hands during trading. A decline of 17% from the average session volume of 830,139 shares. The stock had previously closed at $21.94. A number of research firms have weighed in […]
- 04/08/2020
|
Cubist Systematic Strategies LLC Buys 28,989 Shares of CareDx Inc (NASDAQ:CDNA)
- Cubist Systematic Strategies LLC boosted its stake in CareDx Inc (NASDAQ:CDNA) by 486.2% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 34,951 shares of the company’s stock after purchasing an additional 28,989 shares during the quarter. Cubist Systematic Strategies LLC […]
- 04/08/2020
|
CareDx Sees Prelim. Q1 Sales $38.3M vs $37.76M Est.
|
Zacks: Brokerages Anticipate CareDx Inc (NASDAQ:CDNA) Will Post Earnings of -$0.02 Per Share
- Equities analysts expect that CareDx Inc (NASDAQ:CDNA) will announce ($0.02) earnings per share for the current quarter, according to Zacks. Four analysts have issued estimates for CareDx’s earnings. The highest EPS estimate is $0.05 and the lowest is ($0.16). CareDx reported earnings of $0.05 per share in the same quarter last year, which suggests a […]
- 04/07/2020
|
AQR Capital Management LLC Sells 94,048 Shares of CareDx Inc (NASDAQ:CDNA)
- AQR Capital Management LLC trimmed its position in shares of CareDx Inc (NASDAQ:CDNA) by 64.7% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 51,238 shares of the company’s stock after selling 94,048 shares during the period. AQR Capital Management […]
- 04/07/2020
|
CareDx Supports Launch of International COVID-19 Transplant Registry (C19TxR)
- SOUTH SAN FRANCISCO, Calif., April 06, 2020 -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of.
- 04/06/2020
|
CareDx Supports Launch of International COVID-–9 Transplant Registry (C–9TxR)
|
CareDx Inc (NASDAQ:CDNA) Position Lessened by Goldman Sachs Group Inc.
- Goldman Sachs Group Inc. trimmed its position in shares of CareDx Inc (NASDAQ:CDNA) by 32.9% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 497,679 shares of the company’s stock after selling 243,902 shares during the period. Goldman Sachs […]
- 04/05/2020
|
$37.56 Million in Sales Expected for CareDx Inc (NASDAQ:CDNA) This Quarter
- Wall Street brokerages forecast that CareDx Inc (NASDAQ:CDNA) will post $37.56 million in sales for the current quarter, Zacks Investment Research reports. Four analysts have provided estimates for CareDx’s earnings, with the highest sales estimate coming in at $38.20 million and the lowest estimate coming in at $36.90 million. CareDx reported sales of $25.98 million […]
- 04/04/2020
|
Is There An Opportunity With CareDx, Inc's (NASDAQ:CDNA) 54% Undervaluation?
- How far off is CareDx, Inc (NASDAQ:CDNA) from its intrinsic value? Using the most recent financial data, we'll take a...
- 04/02/2020
|
CareDx (NASDAQ:CDNA) Downgraded by ValuEngine to "Buy"
- CareDx (NASDAQ:CDNA) was downgraded by research analysts at ValuEngine from a “strong-buy” rating to a “buy” rating in a note issued to investors on Thursday, ValuEngine reports. Other research analysts also recently issued reports about the stock. Piper Sandler restated a “buy” rating and set a $63.00 target price on shares of CareDx in a […]
- 04/02/2020
|
Key Takeaways From AMD's Financial Analyst Day
- #1-ranked industry analyst Patrick Moorhead takes a look into AMD's Financial Analyst Day and how it laid the foundation of expectations for the coming years.
- 03/30/2020
|
Bamco Inc. NY Has $9 Million Stake in CareDx Inc (NASDAQ:CDNA)
- Bamco Inc. NY increased its stake in shares of CareDx Inc (NASDAQ:CDNA) by 141.5% during the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 417,036 shares of the company’s stock after acquiring an additional 244,337 shares during the period. Bamco Inc. NY’s holdings in CareDx were […]
- 03/28/2020
|
Caredx Trying To Close In On Key Technical Benchmark
|
Edited Transcript of CDNA earnings conference call or presentation 27-Feb-20 9:30pm GMT
- Q4 2019 CareDx Inc Earnings Call
- 03/25/2020
|
Does This Valuation Of CareDx, Inc (NASDAQ:CDNA) Imply Investors Are Overpaying?
- Today we'll do a simple run through of a valuation method used to estimate the attractiveness of CareDx, Inc...
- 03/24/2020
|
Edited Transcript of CDNA earnings conference call or presentation 27-Feb-20 9:30pm GMT
- Q4 2019 CareDx Inc Earnings Call
- 03/23/2020
|
Analysts Are Bullish on Top Healthcare Stocks: CareDx (CDNA), ObsEva SA (OBSV)
- There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on CareDx (CDNA), ObsEva SA (OBSV) and Axsome Therapeutics
- 03/23/2020
|
Analysts Are Bullish on Top Healthcare Stocks: CareDx (CDNA), ObsEva SA (OBSV)
- There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on CareDx (
CDNA
–
Research Report
), ObsEva SA (
OBSV
–
Research Report
) and Axsome Therapeutics (
AXSM
–
Research Report
) with bullish sentiments.
CareDx
- 03/23/2020
|
REPEAT - New AJT Publication: AlloSure Monitors First Patient Retransplanted After Anti-PD-L1 Cancer Therapy
- CareDx, Inc. (CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, announces today that the American Journal of Transplantation (AJT) published a case report from Johns Hopkins on a successful kidney retransplantation in a patient who experienced rejection of a first kidney transplant after undergoing immune-stimulating therapy for the treatment of metastatic cutaneous squamous cell carcinoma (CSCC). AlloSure was used following the retransplantation to monitor for allograft rejection.
- 03/20/2020
|
REPEAT - New AJT Publication: AlloSure Monitors First Patient Retransplanted After Anti-PD-L1 Cancer Therapy
- CareDx Congratulates Johns Hopkins on Successful Follow-Up Using AlloSure of First Retransplant Patient After Immunotherapy
- 03/20/2020
|
CareDx (NASDAQ:CDNA) Sets New 12-Month Low on Insider Selling
- Shares of CareDx Inc (NASDAQ:CDNA) reached a new 52-week low on Wednesday following insider selling activity. The stock traded as low as $13.04 and last traded at $13.34, with a volume of 437311 shares changing hands. The stock had previously closed at $15.32. Specifically, insider Sasha King sold 7,390 shares of the company’s stock in […]
- 03/20/2020
|
New AJT Publication: AlloSure Monitors First Patient Retransplanted After Anti-PD-L1 Cancer Therapy
- CareDx, Inc. (CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, announces today that the American Journal of Transplantation (AJT) published a case report from Johns Hopkins on a successful kidney retransplantation in a patient who experienced rejection of a first kidney transplant after undergoing immune-stimulating therapy for the treatment of metastatic cutaneous squamous cell carcinoma (CSCC). AlloSure was used following the retransplantation to monitor for allograft rejection.
- 03/20/2020
|
New AJT Publication: AlloSure Monitors First Patient Retransplanted After Anti-PD-L1 Cancer Therapy
- CareDx Congratulates Johns Hopkins on Successful Follow-Up Using AlloSure of First Retransplant Patient After Immunotherapy
- 03/20/2020
|
CareDx Announces New AJT Publication: AlloSure Monitors First Patient Retransplanted After Anti-PD-L1 Cancer Therapy
|
Spok Appoints Christine Cournoyer to Board of Directors
- Spok Holdings, Inc. (NASDAQ: SPOK), a global leader in healthcare communications, today announced that, effective immediately, it has appointed Christine M. Cournoyer, who most recently served as the Chairperson and Chief Executive Officer of N-of-One, Inc., to its Board of Directors. Cournoyer led the
- 03/19/2020
|
ArrowMark Colorado Holdings LLC Has $15.17 Million Holdings in CareDx Inc (NASDAQ:CDNA)
- ArrowMark Colorado Holdings LLC raised its holdings in shares of CareDx Inc (NASDAQ:CDNA) by 17.9% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 703,315 shares of the company’s stock after purchasing an additional 106,796 shares during the period. ArrowMark Colorado […]
- 03/19/2020
|
The Daily Biotech Pulse: Pfizer's Eczema Drug Aces Latestage Study, Orphan Drug Designation For Dicerna, Dyadic's COVID-19 Connection
- Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week highs on March 18)
Biomerica, Inc. (NASDAQ...
- 03/19/2020
|
Wall Street Analysts Are Bullish on Top Healthcare Picks
- There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Novus Therapeutics (NVUS) and CareDx (CDNA) with bullish
- 03/18/2020
|
Wall Street Analysts Are Bullish on Top Healthcare Picks
- There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Novus Therapeutics
- 03/18/2020
|
The Daily Biotech Pulse: AbbVie, Allergan Agree On Divestments, Obalon Stops Obesity Balloon Sale, COVID-19 Updates
- Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on March 17) …
- 03/18/2020
|
Are Options Traders Betting on a Big Move in CareDx (CDNA) Stock?
- Investors need to pay close attention to CareDx (CDNA) stock based on the movements in the options market lately.
- 03/17/2020
|
Are Options Traders Betting on a Big Move in CareDx (CDNA) Stock?
- Investors need to pay close attention to CareDx (CDNA) stock based on the movements in the options market lately.
- 03/17/2020
|
The Daily Biotech Pulse: Setback For DBV In Peanut Allergy Patch Review, Roche Starts Coronavirus Test Shipment, Regeneron Aims For 'Cocktail' COVID-19 Treatment
- Here's a roundup of top developments in the biotech space over the last 24 hours:Scaling The Peaks (Biotech stocks that hit 52-week highs March 16.) * BioNTech SE - ADR (NASDAQ: BNTX) (announced efforts to develop a vaccine for COVID-19) * SUMMIT THERAPEU/S ADR (NASDAQ: SMMT)Down In The Dumps
- 03/17/2020
|
CareDx Launches RemoTraC: Home-Based Monitoring of Transplant Patients
- CareDx, Inc. (CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announces the launch of RemoTraC, a solution enabling remote home-based monitoring of transplant patients. Transplant patients require frequent blood tests which normally require in-person visits to draw sites at labs or hospitals. In close coordination with transplant centers, CareDx will now provide RemoTraC, a remote home-based blood draw solution using mobile phlebotomy for AlloSure and AlloMap surveillance tests, as well as for other standard monitoring tests.
- 03/17/2020
|
Insider Selling: CareDx Inc (NASDAQ:CDNA) CEO Sells 10,000 Shares of Stock
- CareDx Inc (NASDAQ:CDNA) CEO Peter Maag sold 10,000 shares of the stock in a transaction that occurred on Monday, March 16th. The stock was sold at an average price of $17.39, for a total value of $173,900.00. Following the completion of the transaction, the chief executive officer now directly owns 489,909 shares of the company’s […]
- 03/17/2020
|
CareDx Launches RemoTraC Home-Based Monitoring Of Transplant Patients
|
CareDx (NASDAQ:CDNA) Stock Price Down 13.9%
- CareDx Inc (NASDAQ:CDNA) shares dropped 13.9% on Wednesday . The company traded as low as $18.89 and last traded at $18.94, approximately 1,101,124 shares changed hands during mid-day trading. An increase of 34% from the average daily volume of 821,153 shares. The stock had previously closed at $22.00. CDNA has been the topic of a […]
- 03/13/2020
|
Charles Schwab Investment Management Inc. Reduces Position in CareDx Inc (NASDAQ:CDNA)
- Charles Schwab Investment Management Inc. cut its holdings in shares of CareDx Inc (NASDAQ:CDNA) by 3.7% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 254,410 shares of the company’s stock after selling 9,820 shares during the quarter. Charles Schwab […]
- 03/13/2020
|
The Daily Biotech Pulse: Roche Obtains FDA Emergency Use Authorization For COVID-19 Test, Chembio Appoints New CEO, Inovio Slumps On Earnings
- Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech stocks that hit 52-week highs March 12.)
Masimo...
- 03/13/2020
|
Stocks That Hit 52-Week Lows On Thursday
|
CareDx Joins National Kidney Foundation on World Kidney Day to Support Kidney Transplant Community
- SOUTH SAN FRANCISCO, Calif., March 12, 2020 -- CareDx, Inc. (Nasdaq: CDNA), a leader in precision medicine company focused on the discovery, development, and commercialization.
- 03/12/2020
|
$37.61 Million in Sales Expected for CareDx Inc (NASDAQ:CDNA) This Quarter
- Equities research analysts predict that CareDx Inc (NASDAQ:CDNA) will post $37.61 million in sales for the current quarter, according to Zacks Investment Research. Four analysts have made estimates for CareDx’s earnings, with estimates ranging from $37.00 million to $38.20 million. CareDx reported sales of $25.98 million during the same quarter last year, which indicates a […]
- 03/12/2020
|
CareDx Joins National Kidney Foundation on World Kidney Day to Support Kidney Transplant Community
|
Barclays PLC Buys 21,927 Shares of CareDx Inc (NASDAQ:CDNA)
- Barclays PLC raised its holdings in shares of CareDx Inc (NASDAQ:CDNA) by 98.9% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 44,094 shares of the company’s stock after acquiring an additional 21,927 shares during the quarter. Barclays PLC owned about 0.10% of CareDx […]
- 03/11/2020
|
Bank of Montreal Can Buys 63,932 Shares of CareDx Inc (NASDAQ:CDNA)
- Bank of Montreal Can raised its stake in CareDx Inc (NASDAQ:CDNA) by 158.1% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 104,374 shares of the company’s stock after buying an additional 63,932 shares during the period. Bank of Montreal Can owned about 0.25% of […]
- 03/10/2020
|
Brokerages Expect CareDx Inc (NASDAQ:CDNA) Will Post Earnings of $0.02 Per Share
- Analysts expect that CareDx Inc (NASDAQ:CDNA) will post $0.02 earnings per share (EPS) for the current fiscal quarter, Zacks Investment Research reports. Four analysts have made estimates for CareDx’s earnings, with the lowest EPS estimate coming in at $0.01 and the highest estimate coming in at $0.05. CareDx posted earnings of $0.05 per share during […]
- 03/10/2020
|
